NASDAQ:CNTB
Connect Biopharma Holdings Ltd American Stock News
$1.52
-0.0500 (-3.18%)
At Close: May 07, 2024
Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript
08:51pm, Tuesday, 13'th Sep 2022
Connect Biopharma Holdings Limited (NASDAQ:CNTB ) Q2 2022 Results Conference Call September 13, 2022 4:30 PM ET Company Participants Ina McGuinness - IR Dr. Zheng Wei - Co-Founder and CEO Dr. Chin Lee
Connect Biopharma to Report First Half 2022 Financial Results on September 13
08:00am, Thursday, 01'st Sep 2022
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT
Hot Penny Stocks That Are Climbing Right Now
08:11pm, Wednesday, 29'th Jun 2022
Can these penny stocks climb this week? The post Hot Penny Stocks That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy
01:33pm, Wednesday, 08'th Jun 2022
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study
07:54am, Wednesday, 04'th May 2022
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numer
Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
07:00am, Wednesday, 09'th Feb 2022
SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
12:55pm, Thursday, 13'th Jan 2022
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year
Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint
07:19am, Friday, 19'th Nov 2021
Connect Biopharma Holdings Limited (NASDAQ: CNTB) has reported topline results from the Phase 2 trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic de
Connect Biopharma to Participate at Upcoming Conferences
08:00am, Thursday, 11'th Nov 2021
SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage bi
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
08:00am, Tuesday, 19'th Oct 2021
SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopha
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
04:05pm, Tuesday, 31'st Aug 2021
- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -
Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021
08:00am, Wednesday, 25'th Aug 2021
SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmac
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
04:05pm, Monday, 23'rd Aug 2021
TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmac
Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference
08:00am, Wednesday, 26'th May 2021
SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmace
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
